CIK 0001515673
- Large accelerated filer
Ultragenyx Pharmaceutical Inc.
Sign in to watch- Ticker
- RARE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 272546083
- Phone
- +1 415-483-8800
- Business address
- 60 LEVERONI COURT, NOVATO, CA, 94949
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $127,561
- in 3 filings, $17K under 10b5-1 plans
Net −$127,561. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-03-01 | Dier Mardi CFO & Executive Vice President | Grant or award · Stock Option (Right to Buy) | +11,000 | 11,000 | ||
| 2021-03-01 | Bedrosian Camille L EVP and Chief Medical Officer | Grant or award | +5,500 | 39,046 | ||
| 2021-03-01 | Bedrosian Camille L EVP and Chief Medical Officer | Grant or award | +4,636 | 43,682 | ||
| 2021-03-01 | Bedrosian Camille L EVP and Chief Medical Officer | Sale | −4,543 | $138.18 | $628K | 39,139 |
| 2021-03-01 | Bedrosian Camille L EVP and Chief Medical Officer | Grant or award · Stock Option (Right o Buy) | +11,000 | 11,000 | ||
| 2021-03-01 | KAKKIS EMIL D President & CEO | Grant or award | +18,000 | 596,941 | ||
| 2021-03-01 | KAKKIS EMIL D President & CEO | Grant or award | +15,453 | 612,394 | ||
| 2021-03-01 | KAKKIS EMIL D President & CEO | Shares withheld for taxes | −16,342 | $142.47 | $2.3M | 596,052 |
| 2021-03-01 | KAKKIS EMIL D President & CEO | Sale | −30,000 | $141.80 | $4.3M | 2,289,741 |
| 2021-03-01 | KAKKIS EMIL D President & CEO | Grant or award · Stock Option (Right to Buy) | +36,000 | 36,000 | ||
| 2021-02-23 | Aliski William Director | Gift | −1,000 | 64,704 | ||
| 2021-02-19 | Aliski William Director | Exercise or conversion | +7,500 | $97.85 | $734K | 73,204 |
| 2021-02-19 | Aliski William Director | Sale | −7,500 | $149.01 | $1.1M | 65,704 |
| 2021-02-19 | Aliski William Director | Exercise or conversion · Stock Option (Right to Buy) | −7,500 | 0 | ||
| 2021-01-30 | Bedrosian Camille L EVP and Chief Medical Officer | Sale | −2,243 | $140.36 | $315K | 33,546 |
| 2021-01-15 | Bedrosian Camille L EVP and Chief Medical Officer | Exercise or conversion | +25,000 | $55.00 | $1.4M | 60,789 |
| 2021-01-15 | Bedrosian Camille L EVP and Chief Medical Officer | Sale | −25,000 | $139.18 | $3.5M | 35,789 |
| 2021-01-15 | Bedrosian Camille L EVP and Chief Medical Officer | Exercise or conversion · Stock Option (Right to Buy) | −25,000 | 63,000 | ||
| 2021-01-07 | Huizenga Theodore Alan SVP, Controller and PAO | Exercise or conversion | +4,000 | $21.00 | $84K | 20,436 |
| 2021-01-07 | Huizenga Theodore Alan SVP, Controller and PAO | Sale | −4,000 | $140.65 | $563K | 15,716 |
Page 22 of 32 · 632 trades